Iambic Therapeutics prices $16 IPO, raises $150 million
Iambic Therapeutics priced its initial public offering at $16 per share, selling 9.375 million shares to raise $150 million. The shares began trading on Nasdaq under the ticker IAM on October 15, 2026. Joint book‑runners JPMorgan, Jefferies, Bank of America and Citigroup have a 30‑day option to purchase up to 1,406,250 additional shares at the IPO price.
Why it matters
The company says the net proceeds will fund three early‑stage oncology programs, expanding its AI‑driven drug pipeline. The listing creates a new publicly traded AI‑biotech asset, giving investors exposure to the sector and potentially altering ownership stakes as private investors’ holdings dilute.
Key facts
- 1IPO price was $16 per share. tradingview.com
- 29.375 million shares were offered. investing.com
- 3Gross proceeds of $150 million were raised. investing.com
- 4Trading on Nasdaq began on October 15, 2026 under the ticker IAM. tradingview.com
- 5J.P. Morgan, Jefferies, BofA Securities and Citigroup are joint book‑running managers. investing.com
- 6Underwriters have a 30‑day option to buy up to 1,406,250 additional shares at the IPO price. qz.com
Open questions
- Market value reported as $758 million (source 5), $877 million (source 6), and $896 million (source 10).
Summary written by AlphAI AI Desk from 10 of 10 sources. Not investment advice. Figures are as stated by the linked sources.